Relationship between TCM syndrome differentiation with gastro-intestinal function and abnormal electrogastrogram in patients of chronic obstructive pulmonary disease and pulmonary heart disease

1996 ◽  
Vol 2 (3) ◽  
pp. 204-206
Author(s):  
Hui-Juan Hu ◽  
Zhi-Cheng Lian ◽  
Xue-Fen Liang ◽  
Feng Zhan ◽  
Sheng-Gang Shi
2016 ◽  
Vol 97 (3) ◽  
pp. 400-404
Author(s):  
N E Aidargalieva ◽  
A Zh Teleusheva

Chronic pulmonary heart disease is a common pathology and has become one of the leading causes of disability and death in recent years [15]. According to the literature, two-thirds of patients with chronic obstructive pulmonary disease die during the period from 15 months to 5 years after the circulatory decompensation onset, which occupies the third place after hypertension and coronary heart disease among causes of death in the age group older than 50 years [14]. Pulmonary hypertension is considered to be the main pathogenetic mechanism of chronic pulmonary heart disease [11]. The mortality rate in patients with chronic pulmonary heart disease is directly related to the level of pulmonary artery systolic blood pressure. Thus, according to literature data, at the pulmonary artery systolic pressure from 30 to 50 mm Hg 4-5-year survival rate is 30%, and at the level of more than 50 mm Hg 5-year survival rate is zero [1]. Thus, pulmonary hypertension is a poor prognostic factor. Furthermore, it is known that the changes identified in the right ventricle amid the pulmonary hypertension are survival predictors in patients with chronic obstructive pulmonary disease [18]. Literature review showed that the hemodynamics feature in patients with chronic pulmonary heart disease is increased pressure in the pulmonary artery, which leads to both ventricles remodeling and in particular to the right heart enlargement, rise of both right and left ventricles diastolic dysfunction, reduced stroke volume and cardiac output. Furthermore, the review describes that such drug classes as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers and selective β-blockers are successfully used for the revealed disorders correction in patients with chronic pulmonary heart disease.


Sign in / Sign up

Export Citation Format

Share Document